ClinicalTrials.gg
CompletedNCT06370715Updated Sep 28, 2026Results posted

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

A Phase 4 interventional study of Insulin Lispro-aabc and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 12 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

How we know

Updated Sep 28, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.

Enrollment
16th of 36
153 · median 127
Started
2024
the only one that year
Phase 4
15 of 36
none open now
Registered
36th of 36
by date
Lead sponsor
26 of 36
Eli Lilly and Company

Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is the only one that started in 2024, is one of 15 in phase 4, and was the 36th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.

The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes mellitus, type 2 diabetes, Lyumjev, basaglar, Humalog
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes Mellitus (T2DM) for ≥1 year prior to screening
  • Treated for ≥90 days prior to screening with multiple daily injection (MDI) therapy

    • on basal insulin or insulin glargine 100 U/mL [Basaglar or Lantus] or insulin glargin 300 U/mL, insulin determir, insulin degludec U-100, or neutral protamine Hagedorn (NPH) insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro 100 U/mL or 200 U/mL, insulin aspart, insulin glulisine, regular insulin, fast-acting insulin aspart), or
    • premixed analog or human insulin regimens with any basal and bolus insulin
  • May have been treated with up to 3 oral antihyperglycemic medications (OAMs) including metformin, sodium-glucose cotransporter (SGLT)-2 inhibitor in accordance with local regulations. The dose of all OAMs must have been stable for ≥90 days prior to screening
  • Have an value ≥7.5% and ≤10% according to the central laboratory at screening
  • ≤45.0 kg/m²
  • Have access to a telephone, or alternative means for close monitoring/communications
  • Have refrigeration at home or have ready access to refrigeration for storage of insulin therapy
  • Have a regular wake-sleep schedule (awake-work during the day and sleep during the night)

Exclusion criteria

Exclusion Criteria:

  • Having any other condition (including known drug or alcohol abuse, psychiatric disorder including eating disorder) that precludes the subject from following and completing the protocol
  • Have been diagnosed, at any time, with type 1 diabetes mellitus (T1DM) or latent diabetes in adults
  • Have hypoglycemia unawareness as judged by the investigator
  • Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within the 6 months prior to screening
  • Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening
  • Have a known diagnosis of secondary diabetes (for example, diabetes caused by hemochromatosis, acromegaly, chronic pancreatitis, or pancreatectomy)
  • Excessive insulin resistance defined as having received a total daily dose of insulin >2.0 U/kg at the time of screening
  • Have a history of or are being evaluated for bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve
  • Have cardiovascular disease, within the past 6 months prior to screening, defined as stroke, decompensated heart failure ( Class III or IV), myocardial infarction, unstable angina pectoris, or coronary arterial bypass graft
  • History of renal transplantation
  • Currently receiving renal dialysis
  • Serum creatinine >2.0 mg/dL (177 µmol/L) at screening
  • Have obvious clinical signs or symptoms of liver disease (for example, acute or chronic hepatitis or cirrhosis), or elevated liver enzyme measurements
  • Have active or untreated , have been in remission from malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at an increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator
  • Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hemoglobinopathy, anemia, or any other traits known to interfere with measurement of HbA1
  • Have presence of clinically significant gastrointestinal disease (for example, clinically active gastroparesis associated with wide glucose fluctuations) in the investigator's opinion
  • Have used thiazolidinediones, glucagon-like peptide 1 receptor agonist, or pramlintide within 90 days prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Insulin Lispro-aabc

    Participants received subcutaneous injections of insulin lispro-aabc 100 units/millilitre (U/mL) immediately (0 to 2 minutes) before each meal, in combination with once-daily insulin glargine 100 U/mL as basal insulin, during the 26-week treatment period.

    Drug: Insulin Lispro-aabc · Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)

    The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.

    Time frame: Baseline through Week 26

  2. Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dL

    Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

    Time frame: Baseline through Week 26

Secondary outcomes

  1. Percentage of Participants With Severe Hypoglycemia

    * Severe hypoglycemia is considered any hypoglycemic event where the participant requires assistance for recovery with or without hospitalisation and is reported as a serious adverse event. * The percentage of participants with at least 1 severe hypoglycemic event was calculated as the number of participants with \>=1 severe hypoglycemic event divided by the total number of participants, multiplied by 100.

    Time frame: Baseline through Week 26

  2. Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL

    * Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.

    Time frame: Baseline through Week 26

  3. Rate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL

    * Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

    Time frame: Baseline through Week 26

  4. Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL

    * Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.

    Time frame: Baseline through Week 26

  5. Rate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL

    * Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

    Time frame: Baseline through Week 26

  6. Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL

    The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.

    Time frame: Baseline through Week 26

  7. Rate of Documented Hypoglycemia With Blood Glucose <70 mg/dL

    Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

    Time frame: Baseline through Week 26

  8. Change From Baseline in Body Weight

    Time frame: Baseline, Week 26

  9. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Baseline, Week 26

  10. Percentage of Participants Achieving HbA1c < 7%

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 26

  11. Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score

    The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin under 5 domains: Inconvenience of Regimen \[5 items\], Lifestyle Flexibility \[3 items\], Glycemic Control \[3 items\], Hypoglycemic Control \[5 items\], Insulin Delivery Device \[6 items\]. Each Item is measured on a 7-point scale. The overall score is calculated as the mean of all 22 items and transformed to a scale of 0 to 100 using the formula: 100\*\[(7 - raw overall score)/6\], with higher scores indicating better treatment satisfaction.

    Time frame: Baseline, Week 26

  12. Change From Baseline in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) Values

    Time frame: Baseline, Day 3 of Week 20

  13. Change From Baseline in Bolus Insulin Dose, Basal Insulin Dose

    * Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days.

    Time frame: Baseline, Week 20

  14. Change From Baseline in Basal to Bolus Insulin Dose Ratio

    Basal to Bolus insulin dose ratio, calculated as the basal insulin dose divided by the basal insulin dose. * Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days

    Time frame: Baseline, Week 20

  15. Change From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values

    SMBG measurements were taken at 9 time points: fasting, 1 hour post-breakfast, 2 hours post-breakfast, pre-lunch, 1 hour post-lunch, 2 hours post-lunch, pre-dinner, 1 hour post-dinner, and 2 hours post-dinner. The SMBG value was calculated as the average of the corresponding SMBG measurements collected on Days 1, 2, and 3 across cumulative non-missing data days.

    Time frame: Baseline, Week 20

07

Results

Posted Sep 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneInsulin Lispro-aabc
Started153
Received at least one dose of insulin lispro-aabc150
Completed144
Not completed9
Withdrew: Withdrawal by subject7
Withdrew: Adverse event2

Outcome measures

PrimaryPercentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)

The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)
percentage of participantsInsulin Lispro-aabc
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)4
PrimaryRate of Documented Hypoglycemia With Blood Glucose <54 mg/dL

Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

Time frame:
Baseline through Week 26
Reported as:
Number · events/participant/year
Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dL
events/participant/yearInsulin Lispro-aabc
Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dL0.08
SecondaryPercentage of Participants With Severe Hypoglycemia

* Severe hypoglycemia is considered any hypoglycemic event where the participant requires assistance for recovery with or without hospitalisation and is reported as a serious adverse event. * The percentage of participants with at least 1 severe hypoglycemic event was calculated as the number of participants with \>=1 severe hypoglycemic event divided by the total number of participants, multiplied by 100.

Time frame:
Baseline through Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With Severe Hypoglycemia
Percentage of participantsInsulin Lispro-aabc
Percentage of Participants With Severe Hypoglycemia0
SecondaryPercentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL

* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL
percentage of participantsInsulin Lispro-aabc
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL0.7
SecondaryRate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL

* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

Time frame:
Baseline through Week 26
Reported as:
Number · events/participant/year
Rate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL
events/participant/yearInsulin Lispro-aabc
Rate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL0.01
SecondaryPercentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL

* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL
percentage of participantsInsulin Lispro-aabc
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL4
SecondaryRate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL

* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

Time frame:
Baseline through Week 26
Reported as:
Number · events/participant/year
Rate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL
events/participant/yearInsulin Lispro-aabc
Rate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL0.08
SecondaryPercentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL

The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL
percentage of participantsInsulin Lispro-aabc
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL22
SecondaryRate of Documented Hypoglycemia With Blood Glucose <70 mg/dL

Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.

Time frame:
Baseline through Week 26
Reported as:
Number · events/participant/year
Rate of Documented Hypoglycemia With Blood Glucose <70 mg/dL
events/participant/yearInsulin Lispro-aabc
Rate of Documented Hypoglycemia With Blood Glucose <70 mg/dL0.77
SecondaryChange From Baseline in Body Weight
Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Insulin Lispro-aabc
Change From Baseline in Body Weight0.3 ± 0.18
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cInsulin Lispro-aabc
Change From Baseline in Hemoglobin A1c (HbA1c)-0.8 ± 0.11
SecondaryPercentage of Participants Achieving HbA1c < 7%

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c < 7%
percentage of participantsInsulin Lispro-aabc
Percentage of Participants Achieving HbA1c < 7%21.6
SecondaryChange From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score

The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin under 5 domains: Inconvenience of Regimen \[5 items\], Lifestyle Flexibility \[3 items\], Glycemic Control \[3 items\], Hypoglycemic Control \[5 items\], Insulin Delivery Device \[6 items\]. Each Item is measured on a 7-point scale. The overall score is calculated as the mean of all 22 items and transformed to a scale of 0 to 100 using the formula: 100\*\[(7 - raw overall score)/6\], with higher scores indicating better treatment satisfaction.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
score on a scaleInsulin Lispro-aabc
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score5.7 ± 0.86
SecondaryChange From Baseline in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) Values
Time frame:
Baseline, Day 3 of Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) Values
mg/dLInsulin Lispro-aabc
1-hour Postprandial-19.2 ± 3.29
2-hour Postprandial-22.2 ± 3.29
SecondaryChange From Baseline in Bolus Insulin Dose, Basal Insulin Dose

* Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days.

Time frame:
Baseline, Week 20
Reported as:
Least squares mean · Units/day
Change From Baseline in Bolus Insulin Dose, Basal Insulin Dose
Units/dayInsulin Lispro-aabc
Bolus Insulin Dose3.5 ± 0.72
Basal insulin Dose2.6 ± 0.52
SecondaryChange From Baseline in Basal to Bolus Insulin Dose Ratio

Basal to Bolus insulin dose ratio, calculated as the basal insulin dose divided by the basal insulin dose. * Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days

Time frame:
Baseline, Week 20
Reported as:
Least squares mean · ratio
Change From Baseline in Basal to Bolus Insulin Dose Ratio
ratioInsulin Lispro-aabc
Change From Baseline in Basal to Bolus Insulin Dose Ratio0.0 ± 0.02
SecondaryChange From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values

SMBG measurements were taken at 9 time points: fasting, 1 hour post-breakfast, 2 hours post-breakfast, pre-lunch, 1 hour post-lunch, 2 hours post-lunch, pre-dinner, 1 hour post-dinner, and 2 hours post-dinner. The SMBG value was calculated as the average of the corresponding SMBG measurements collected on Days 1, 2, and 3 across cumulative non-missing data days.

Time frame:
Baseline, Week 20
Reported as:
Mean · mg/dL
Change From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values
mg/dLInsulin Lispro-aabc
Change From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values-18.0 ± 40.57

Adverse events

Collected over Baseline to end of safety follow-up (up to 42 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Lispro-aabc0/150 (0%)4/150 (2.7%)49/150 (32.7%)
Most frequent serious events
Most frequent serious events
EventInsulin Lispro-aabc
Angina unstableCardiac disorders1/150
CataractEye disorders1/150
GastritisGastrointestinal disorders1/150
Radius fractureInjury, poisoning and procedural complications1/150
HyperglycaemiaMetabolism and nutrition disorders1/150
Most frequent other events
Showing 10 of 39
Most frequent other events
EventInsulin Lispro-aabc
PyrexiaGeneral disorders6/150
Abdominal distensionGastrointestinal disorders5/150
Injection site painGeneral disorders5/150
Injection site erythemaGeneral disorders4/150
ObesityMetabolism and nutrition disorders3/150
Burning sensationNervous system disorders3/150
HeadacheNervous system disorders3/150
NasopharyngitisInfections and infestations2/150
ArthralgiaMusculoskeletal and connective tissue disorders2/150
Pain in extremityMusculoskeletal and connective tissue disorders2/150

Baseline characteristics

All participants who received at least one dose of insulin lispro-aabc.

Age, Continuous
Age, Continuous(years)Insulin Lispro-aabc
Mean56.6 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Lispro-aabc
Female65
Male85
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Lispro-aabc
American Indian or Alaska Native0
Asian150
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Insulin Lispro-aabc
India150
08

Study locations

12 sites
  • Osmania Medical College & Hospital
    Hyderabad, Andhra Pradesh 500012, India
  • King George Hospital, Visakhapatnam
    Visakhapatnam, Andhra Pradesh 530002, India
  • Diabetes Research Centre
    Royapuram, Chennai India 600013, India
  • Vijyaratna Dibetes Diagnosis Treatment Centre
    Ahmedabad, Gujarat 380007, India
  • Center for Diabetes and Endocrine Care
    Bengaluru, Karnataka 560043, India
  • Sahyadri Super Speciality Hospital
    Pune, Maharashtra 411004, India
  • Chellaram Diabetes Institute
    Pune, Maharashtra 411021, India
  • S. P. Medical College & A G Hospital
    Bikaner, Rajasthan 334003, India
  • Rajasthan University of Health Sciences
    Jaipur, Rajasthan 302033, India
  • Kovai Diabetes Speciality Center and Hospital
    Coimbatore, Tamil Nadu 641009, India
  • Brij Medical Center Pvt. Ltd.
    Kanpur, Uttar Pradesh 208020, India
  • Medical College & Hospital, Kolkata
    Kolkata, West Bengal 700073, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Sep 2025, 16 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 16 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 17, 2024
StartActual
Apr 18, 2024
Primary completionActual
Sep 2, 2025
CompletionActual
Sep 2, 2025
Results first posted
Sep 28, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 28, 2026
Enrollment
150→153
Sep 28, 2026
Interventions
Arm changed Insulin Lispro-aabc + Insulin Glargine→Insulin Lispro-aabc
Sep 28, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedPercentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)Time frame: Baseline through Week 26
  • AddedRate of Documented Hypoglycemia With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
  • RemovedPercentage of Participants with at least 1 Episode of HypoglycemiaTime frame: Baseline through Week 26
Sep 28, 2026
Documents
Secondary outcomes
9 edited, 6 added, 3 removed
What changed in the outcomes
  • EditedPercentage of Participants withWith Severe Hypoglycemic EventsHypoglycemiaTime frame: Week 26 → Baseline through Week 26
  • EditedChange fromFrom Baseline to Week 26 in Body WeightTime frame: Baseline, Week 26
  • EditedChange fromFrom Baseline to Week 26 in Insulin Treatment Satisfaction QuestionnaireHemoglobin A1c (ITSQHbA1c) ScoreTime frame: Baseline, Week 26
  • EditedChange fromFrom Baseline to Week 26 in Hemoglobin A1cInsulin Treatment Satisfaction Questionnaire (HbA1cITSQ) ScoreTime frame: Baseline, Week 26
  • EditedPercentage of Participants Achieving HbA1c Less Than (<) 7%Time frame: Week 26
  • EditedChange fromFrom Baseline to Week 26 in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) ValuesTime frame: Baseline, Week 26 → Baseline, Day 3 of Week 20
  • EditedChange fromFrom Baseline to Week 26 in Bolus Insulin Dose, Basal Insulin DoseTime frame: Baseline, Week 26 → Baseline, Week 20
  • EditedChange fromFrom Baseline to Week 26 in Basal to Bolus Insulin Dose RatioTime frame: Baseline, Week 26 → Baseline, Week 20
  • EditedChange fromFrom Baseline to Week 26 in 9-Point Self-Monitored Blood Glucose (SMBG) ValuesTime frame: Baseline, Week 26 → Baseline, Week 20
  • AddedPercentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
  • AddedRate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
  • AddedPercentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
  • AddedRate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
  • AddedPercentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
  • AddedRate of Documented Hypoglycemia With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
  • RemovedPercentage of Participants with Nocturnal Hypoglycemia EventsTime frame: Week 26
  • RemovedPercentage of Participants with Nocturnal and All Documented Hypoglycemic EventsTime frame: Week 26
  • RemovedChange from Baseline to Week 26 in Bolus Basal: Bolus RatioTime frame: Baseline, Week 26
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Results posted
    Enrollment 150→153
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedPercentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)Time frame: Baseline through Week 26
    • AddedRate of Documented Hypoglycemia With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
    • RemovedPercentage of Participants with at least 1 Episode of HypoglycemiaTime frame: Baseline through Week 26
    Secondary outcomes 9 edited, 6 added, 3 removed
    What changed in the outcomes
    • EditedPercentage of Participants withWith Severe Hypoglycemic EventsHypoglycemiaTime frame: Week 26 → Baseline through Week 26
    • EditedChange fromFrom Baseline to Week 26 in Body WeightTime frame: Baseline, Week 26
    • EditedChange fromFrom Baseline to Week 26 in Insulin Treatment Satisfaction QuestionnaireHemoglobin A1c (ITSQHbA1c) ScoreTime frame: Baseline, Week 26
    • EditedChange fromFrom Baseline to Week 26 in Hemoglobin A1cInsulin Treatment Satisfaction Questionnaire (HbA1cITSQ) ScoreTime frame: Baseline, Week 26
    • EditedPercentage of Participants Achieving HbA1c Less Than (<) 7%Time frame: Week 26
    • EditedChange fromFrom Baseline to Week 26 in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) ValuesTime frame: Baseline, Week 26 → Baseline, Day 3 of Week 20
    • EditedChange fromFrom Baseline to Week 26 in Bolus Insulin Dose, Basal Insulin DoseTime frame: Baseline, Week 26 → Baseline, Week 20
    • EditedChange fromFrom Baseline to Week 26 in Basal to Bolus Insulin Dose RatioTime frame: Baseline, Week 26 → Baseline, Week 20
    • EditedChange fromFrom Baseline to Week 26 in 9-Point Self-Monitored Blood Glucose (SMBG) ValuesTime frame: Baseline, Week 26 → Baseline, Week 20
    • AddedPercentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
    • AddedRate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
    • AddedPercentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
    • AddedRate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
    • AddedPercentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
    • AddedRate of Documented Hypoglycemia With Blood Glucose <70 mg/dLTime frame: Baseline through Week 26
    • RemovedPercentage of Participants with Nocturnal Hypoglycemia EventsTime frame: Week 26
    • RemovedPercentage of Participants with Nocturnal and All Documented Hypoglycemic EventsTime frame: Week 26
    • RemovedChange from Baseline to Week 26 in Bolus Basal: Bolus RatioTime frame: Baseline, Week 26
    Interventions Arm changed Insulin Lispro-aabc + Insulin Glargine→Insulin Lispro-aabc
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06370715
Collaborators
Cipla Ltd.
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Apr 18, 2024
Primary completion
Sep 2, 2025
Completion
Sep 2, 2025
Results posted
Sep 28, 2026
Last update
Sep 28, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Lispro

Start the discussion